Cole Eye Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Curr Opin Ophthalmol. 2013 May;24(3):233-8. doi: 10.1097/ICU.0b013e32835f8eaa.
To discuss the current combination treatments that involve existing as well as novel drugs that show promise for the treatment of neovascular age-related macular degeneration.
Photodynamic therapy in combination with antivascular endothelial growth factor (VEGF) and steroids is currently used as a second-line therapy in patients not responding to monotherapy with anti-VEGF agents or in whom the treatment burden of monthly injections is too great. It is used as a primary therapy for idiopathic polypoidal choroidal vasculopathy. Radiation and antiplatelet-derived growth factor therapy show promising results and are currently under investigation.
Using combination treatments that target other pathways involved in angiogenesis will hopefully improve on the results of current anti-VEGF agents and may result in greater visual improvement and more convenient dosing regimens.
讨论目前涉及现有和新型药物的联合治疗方案，这些药物有望治疗新生血管性年龄相关性黄斑变性。
光动力疗法联合抗血管内皮生长因子（VEGF）和类固醇目前被用作对单药抗 VEGF 药物治疗无反应的患者或每月注射治疗负担过大的患者的二线治疗。它被用作特发性息肉状脉络膜血管病变的主要治疗方法。放射和抗血小板衍生生长因子治疗显示出有希望的结果，目前正在研究中。
使用针对血管生成中其他途径的联合治疗方法有望改善目前抗 VEGF 药物的治疗效果，并可能导致更显著的视力改善和更方便的给药方案。
